Aridis Pharmaceuticals
General Information | |
Business: |
We are a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. mAbs represent a fundamentally new treatment approach in the infectious disease market and are designed to overcome key issues associated with current therapies, including drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation between treatment alternatives. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 25 |
Founded: | 2003 |
Contact Information | |
Address | 5941 Optical Court, San Jose, CA 95138, US |
Phone Number | (408) 385-1742 |
Web Address | http://www.aridispharma.com |
View Prospectus: | Aridis Pharmaceuticals |
Financial Information | |
Market Cap | $102.57mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-27.6 mil (last 12 months) |
IPO Profile | |
Symbol | ARDS |
Exchange | NASDAQ |
Shares (millions): | 2.0 |
Price range | $13.00 - $13.00 |
Est. $ Volume | $26.0 mil |
Manager / Joint Managers | Cantor |
CO-Managers | Maxim Group/ Northland Capital Markets |
Expected To Trade: | 8/14/2018 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |